LONGENECKER; B. Michael

Patent Applications and Registrations

Patent applications and USPTO patent grants for LONGENECKER; B. Michael.The latest application filed is for "mucinous glycoprotein (muc-1) vaccine".

Company Profile

0.13.13

LONGENECKER; B. Michael - Edmonton CA
Longenecker; B. Michael - Alberta N/A CA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Mucinous Glycoprotein (muc-1) Vaccine App 20160082093 - LONGENECKER; B. Michael	2016-03-24
Method of Treating Patients with a Mucinous Glycoprotein (MUC-1) Vaccine App 20150359868 - LONGENECKER; B. Michael	2015-12-17
Mucinous glycoprotein (MUC-1) vaccine Grant 9,173,929 - Longenecker November 3, 2	2015-11-03
Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine Grant 9,119,784 - Longenecker September 1, 2	2015-09-01
Method of Treating Patients with a Mucinous Glycoprotein (MUC-1) Vaccine App 20150071990 - LONGENECKER; B. Michael	2015-03-12
Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine Grant 8,871,250 - Longenecker October 28, 2	2014-10-28
Vaccine for modulating between T1 and T2 immune responses Grant 8,552,145 - Budzynski , et al. October 8, 2	2013-10-08
Vaccine for Modulating Between T1 and T2 Immune Responses App 20120269884 - Budzynski; Wladyslaw A. ; et al.	2012-10-25
Vaccine for Modulating Between T1 and T2 Immune Responses App 20120269885 - Budzynski; Wladyslaw A. ; et al.	2012-10-25
Vaccine for modulating between T1 and T2 immune responses Grant 8,198,400 - Budzynski , et al. June 12, 2	2012-06-12
Mucinous Glycoprotein (Muc-1) Vaccine App 20080131495 - Longenecker; B. Michael	2008-06-05
Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine App 20070014844 - Longenecker; B. Michael	2007-01-18
Synthetic glyco-lipo-peptides as vaccines App 20060069238 - Koganty; R. Rao ; et al.	2006-03-30
Imunogenic conjugate of carbohydrate haptens and aggregated protein carrier App 20040247608 - Krantz, Mark J ; et al.	2004-12-09
Vaccine for modulating between T1 and T2 immune responses App 20030157160 - Budzynski, Wladyslaw A. ; et al.	2003-08-21
Methods of detecting T-cell activation Grant 6,602,660 - Agrawal , et al. August 5, 2	2003-08-05
Lipid-modified muc-1 derivatives Grant 6,600,012 - Agrawal , et al. July 29, 2	2003-07-29
Enhancement of the cellular immune response Grant RE38,046 - Longenecker , et al. March 25, 2	2003-03-25
MUC-1 antagonists and methods of treating immune disorders App 20020142983 - Agrawal, Babita ; et al.	2002-10-03
Enhancement of the cellular immune response App 20020068071 - Longenecker, B. Michael ; et al.	2002-06-06
MUC-1 as an immunosuppressive therapeutic agent for the treatment of inflammatory and autoimmune conditions App 20020044943 - Longenecker, B. Michael ; et al.	2002-04-18
Human tumor-associated Thomsen-Friedenreich antigen Grant 5,110,911 - Samuel , et al. May 5, 1	1992-05-05
Enhancement of the cellular immune response using carbohydrate primed DTH effector cells expressing the CD5+/CD8- phenotype Grant 4,971,795 - Longenecker , et al. November 20, 1	1990-11-20

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.